{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:32:07Z","timestamp":1791322327250,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84064-1","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:56:45Z","timestamp":1735873005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polypharmacy or potentially inappropriate medications among older adults with COVID-19 in a secondary hospital in China and their association with mortality"],"prefix":"10.1038","volume":"15","author":[{"given":"Mian","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84064_CR1","doi-asserted-by":"crossref","unstructured":"Gao, S-J. et al. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public heal th alert! J. Med. Virol. 94,1255\u20131256.","DOI":"10.1002\/jmv.27491"},{"key":"84064_CR2","doi-asserted-by":"crossref","unstructured":"Menni, C. et al. Symptom prevalence, duration, and risk of hospital admission in indivi duals infected with SARS-CoV-2 during periods of omicron and delta var iant dominance: A prospective observational study from the ZOE COVID S tudy. Lancet 399,1618\u20131624.","DOI":"10.1016\/S0140-6736(22)00327-0"},{"key":"84064_CR3","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/13685538.2020.1774748","volume":"23","author":"M Parohan","year":"2020","unstructured":"Parohan, M. et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. Aging Male. 23, 1416\u20131424 (2020).","journal-title":"Aging Male"},{"key":"84064_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jamda.2021.12.009","volume":"23","author":"M Di Bari","year":"2022","unstructured":"Di Bari, M. et al. COVID-19, vulnerability, and long-term mortality in hospitalized and nonhospitalized older persons. J. Am. Med. Dir. Assoc. 23, 414\u2013420e411 (2022).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"84064_CR5","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1080\/22221751.2022.2128435","volume":"11","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022. Emerg. Microbes Infect. 11, 2800\u20132807 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"84064_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon, N. et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 17, 230 (2017).","journal-title":"BMC Geriatr."},{"key":"84064_CR7","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s00520-020-05759-5","volume":"29","author":"Y Suh","year":"2021","unstructured":"Suh, Y. et al. Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: A population-based study. Support Care Cancer. 29, 3025\u20133034 (2021).","journal-title":"Support Care Cancer"},{"key":"84064_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","volume":"21","author":"LE Davies","year":"2020","unstructured":"Davies, L. E. et al. Adverse outcomes of polypharmacy in older people: Systematic review of reviews. J. Am. Med. Dir. Assoc. 21, 181\u2013187 (2020).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"84064_CR9","doi-asserted-by":"crossref","unstructured":"Toh, J. J. Y. et al. Prevalence and health outcomes of polypharmacy and hyperpolypharmacy in older adults with frailty: A systematic review and meta-analysis. Ageing Res. Rev. 83,101811 (2023).","DOI":"10.1016\/j.arr.2022.101811"},{"key":"84064_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/archinte.1991.00400090107019","volume":"151","author":"MH Beers","year":"1991","unstructured":"Beers, M. H. et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch. Intern. Med. 151, 1825\u20131832 (1991).","journal-title":"Arch. Intern. Med."},{"key":"84064_CR11","doi-asserted-by":"crossref","unstructured":"American Geriatrics Society. 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 71, 2052\u20132081 (2023).","DOI":"10.1111\/jgs.18372"},{"key":"84064_CR12","doi-asserted-by":"publisher","first-page":"e0115521","DOI":"10.1128\/AAC.01155-21","volume":"65","author":"RT Schooley","year":"2021","unstructured":"Schooley, R. T. et al. Rethinking remdesivir: Synthesis, antiviral activity, and pharmacokinetics of oral lipid Prodrugs. Antimicrob. Agents Chemother. 65, e0115521 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"84064_CR13","doi-asserted-by":"crossref","unstructured":"Lee, C. C. et al. Molnupiravir-a novel oral anti-SARS-CoV-2 agent. Antibiotics (Basel). 10,(2021).","DOI":"10.3390\/antibiotics10111294"},{"key":"84064_CR14","doi-asserted-by":"crossref","unstructured":"Singh, A. K. et al. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab. Syndr.. 15,102329(2021).","DOI":"10.1016\/j.dsx.2021.102329"},{"key":"84064_CR15","doi-asserted-by":"crossref","unstructured":"Hung, Y. P. et al. Oral nirmatrelvir\/ritonavir therapy for COVID-19: The dawn in the dark? Antibiotics (Basel). 11,(2022).","DOI":"10.3390\/antibiotics11020220"},{"key":"84064_CR16","unstructured":"National Medical Products Administration has conditionally approved the import registration of Pfizer\u2019. s Novel Coronavirus treatment nematvir\/ritonavir combined package [https:\/\/www.nmpa.gov.cn\/zhuanti\/yqyjzxd\/yqyjxd\/20220212085753142.html]"},{"key":"84064_CR17","doi-asserted-by":"crossref","unstructured":"Chang, C. T. et al. Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals. J. Pharm. Policy Pract. 16,2 (2023).","DOI":"10.1186\/s40545-022-00504-1"},{"key":"84064_CR18","doi-asserted-by":"crossref","unstructured":"Chen, Z. et al. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients. BMC Geriatr.. 23,774(2023).","DOI":"10.1186\/s12877-023-04487-9"},{"key":"84064_CR19","doi-asserted-by":"crossref","unstructured":"Matovelle, P. et al. Polypharmacy in elderly patients: A three-year longitudinal analysis in primary care settings of Arag\u00f3n, Spain. Ann. Geriatr. Med. Res. (2023).","DOI":"10.4235\/agmr.23.0137"},{"key":"84064_CR20","doi-asserted-by":"crossref","unstructured":"Ghasemi, H. et al. Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies. Trop. Med. Health 50,60 (2022).","DOI":"10.1186\/s41182-022-00456-x"},{"key":"84064_CR21","doi-asserted-by":"crossref","unstructured":"Sirois, C. et al. Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: A population-based cohort study among older adults in Quebec, Canada. BMJ Open 12  e060295 (2022).","DOI":"10.1136\/bmjopen-2021-060295"},{"key":"84064_CR22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.sapharm.2019.02.001","volume":"16","author":"VL Cheong","year":"2020","unstructured":"Cheong, V. L. et al. Medication-related risk factors and its association with repeated hospital admissions in frail elderly: A case control study. Res. Soc. Adm. Pharm. 16, 1318\u20131322 (2020).","journal-title":"Res. Social Adm. Pharm."},{"key":"84064_CR23","doi-asserted-by":"crossref","unstructured":"McKeigue, P. M. et al. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: The REACT-SCOT case-control study. BMC Med.. 19,51(2021).","DOI":"10.1186\/s12916-021-02021-5"},{"key":"84064_CR24","doi-asserted-by":"crossref","unstructured":"Filippatos, T. D. et al. Hyponatremia in the elderly: Challenges and solutions. Clin. Interv Aging 12,1957\u20131965(2017).","DOI":"10.2147\/CIA.S138535"},{"key":"84064_CR25","doi-asserted-by":"crossref","unstructured":"Huang, Y. T. et al. The impact of high-risk medications on mortality risk among older adults with polypharmacy: Evidence from the English Longitudinal Study of Ageing. BMC Med.. 19,321(2021).","DOI":"10.1186\/s12916-021-02192-1"},{"key":"84064_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill, S. S. et al. Antipsychotic drug use and mortality in older adults with dementia. Ann. Intern. Med. 146, 775\u2013786 (2007).","journal-title":"Ann. Intern. Med."},{"key":"84064_CR27","doi-asserted-by":"publisher","first-page":"e0258916","DOI":"10.1371\/journal.pone.0258916","volume":"16","author":"B Austria","year":"2021","unstructured":"Austria, B. et al. Mortality in association with antipsychotic medication use and clinical outcomes among geriatric psychiatry outpatients with COVID-19. PLoS One. 16, e0258916 (2021).","journal-title":"PLoS One"},{"key":"84064_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N Engl. J. Med."},{"key":"84064_CR29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study. Lancet 400, 1213\u20131222 (2022).","journal-title":"Lancet"},{"key":"84064_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2\u00a0M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"84064_CR31","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","volume":"69","author":"C Eichbaum","year":"2013","unstructured":"Eichbaum, C. et al. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur. J. Clin. Pharmacol. 69, 1795\u20131800 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"84064_CR32","doi-asserted-by":"publisher","first-page":"106857","DOI":"10.1016\/j.ijantimicag.2023.106857","volume":"62","author":"C Shi","year":"2023","unstructured":"Shi, C. et al. Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China. Int. J. Antimicrob. Agents. 62, 106857 (2023).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"84064_CR33","doi-asserted-by":"crossref","unstructured":"Ross, S. B. et al. Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications. JAMA Netw. Open. 5 e2220184 (2022).","DOI":"10.1001\/jamanetworkopen.2022.20184"},{"key":"84064_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","volume":"63","author":"RM Menon","year":"2015","unstructured":"Menon, R. M. et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir. J. Hepatol. 63, 20\u201329 (2015).","journal-title":"J. Hepatol."},{"key":"84064_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s41999-022-00723-4","volume":"14","author":"AGR Visser","year":"2023","unstructured":"Visser, A. G. R. et al. The impact of polypharmacy on 30-day COVID-related mortality in nursing home residents: A multicenter retrospective cohort study. Eur. Geriatr. Med. 14, 51\u201357 (2023).","journal-title":"Eur. Geriatr. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84064-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84064-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T22:04:04Z","timestamp":1735941844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84064-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84064"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84064-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}